New combo shot aims to tame type 1 diabetes

NCT ID NCT07087795

Ongoing Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-stage trial tests a new weekly injection called NNC0194-0499, alone or with another drug (semaglutide), in 96 adults with type 1 diabetes. The goal is to see if it improves blood sugar levels compared to placebo. All participants continue their usual insulin. The study lasts about 36 weeks and focuses on safety and blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NNC0194-0499 (a new weekly injection) and semaglutide (a diabetes drug)
What this could lead to: If it works, this could point toward a new combination treatment to help people with type 1 diabetes manage their blood sugar levels more effectively.
What could go wrong: This is an early Phase 1 trial with only 96 people, so it is not yet proven to be safe or effective. The results may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Profil Institut für Stoffwechselforschung GmbH

Neuss, 41460, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.